Activation of SHH pathway is an appealing target since inhibitors of SMO were developed and approved for BCC.7,14,15,36 Here, we report 75% of pooled objective response rate and 100% in patients with somatic or germline PTCH1 mutation. Here, SMO is linked to skin basal cell carcinoma.